InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $2.235 0.61 (37.54%)+
Announcement
Release
22 Jul 2026 8:20AM
Price at Release
$1.625
Full Release
download
Summary
PYC Therapeutics Limited, a precision medicine company, announced that the Safety Review Committee has approved a dose escalation to 2.4 mg/kg in the ongoing Phase 1b study of their drug candidate PYC-003 for treating Polycystic Kidney Disease (PKD). This approval follows the review of safety and tolerability data from earlier studies. Additionally, an Open-Label Extension for continuous dosing has been approved, matching the duration of an upcoming registrational trial. The company plans to present safety and efficacy data in 2026 and 2027, with a focus on establishing an optimal dosing regimen for future trials.
Key Points
  • PYC Therapeutics Limited is advancing a drug candidate PYC-003 for Polycystic Kidney Disease (PKD).
  • The Safety Review Committee has approved escalation to a higher dose of 2.4 mg/kg in the Phase 1b study.
  • Approval has been received for an Open-Label Extension to allow continuous dosing up to 24 months.
  • Safety and efficacy data from previous studies are expected to be presented in 2026 and 2027.
  • The company's goal is to determine the safety/tolerability of PYC-003 for a proposed transition to a registrational trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.